AstraZeneca Sees Off Shareholder Revolt Over CEO’s Potential $25m Pay

Investors Upbeat Despite Vaccine Woes

 
• By Andrew McConaghie
  
Pascal Soriot
Soriot is criticized by EU leaders for failing to deliver enough COVID-19 vaccine doses, but is also credited for turning around AZ's fortunes. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip